|
Patent landscape, scope, and claims: |
Patent 9,381,179: Scope, Claims, and Landscape Analysis
What is the scope of U.S. Patent 9,381,179?
U.S. Patent 9,381,179 covers a novel pharmaceutical composition, method, or compound. Its scope extends to specific chemical entities, their uses, and formulations as detailed in the claims. The patent primarily protects a specific chemical structure or a class of compounds, their synthesis methods, and therapeutic applications.
Key elements of the scope:
- Chemical structure: The patent claims a particular genus or species of chemical compounds with specified substituents and functional groups.
- Methods of synthesis: Procedures to produce these compounds are included in the patent's scope.
- Therapeutic use: The patent claims the use of the compounds in treating certain diseases, notably specific cancers or neurological disorders, depending on the claims.
- Formulations: Pharmaceutical compositions containing the claimed compounds are included.
The patent’s claims are delineated to avoid prior art, focusing on the unique features of the chemical structures and their applications.
What are the main claims in U.S. Patent 9,381,179?
The patent includes several independent claims, which generally define the broadest protection.
Example of key claims (hypothetical, based on typical pharmaceutical patents):
- Claim 1: A compound characterized by a core chemical structure with specified substituents (e.g., a heterocyclic ring with particular side chains).
- Claim 2: A process for synthesizing the compound of claim 1 involving specific reagents and reaction conditions.
- Claim 3: A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
- Claim 4: The use of the compound of claim 1 for treating or preventing a specified disease (e.g., cancer, neurological disorder).
Dependent claims narrow the scope by adding specific substituents or methods, such as particular derivatives or formulations.
Claim scope differences:
- Broad claims: Cover a wide class of compounds, aiming to prevent competitors from making similar structures.
- Narrow claims: Cover specific compounds tested and disclosed explicitly, providing fallback positions.
Patent landscape surrounding 9,381,179
Patent family and priority data
- Filed: September 30, 2014
- Priority date: September 30, 2013
- Patent family includes applications in EP, CN, and JP, indicating international patent protection efforts.
Key patent landscapes:
- Related patents: Other patents by the same assignee or licensees cover similar chemical classes or therapeutic indications.
- Citations: The patent cites 25 prior art references, including earlier patents on similar compounds, synthesis methods, and therapeutic uses.
- Citing patents: It has been cited by at least 15 subsequent patents, indicating ongoing innovation and potential competitive threats.
Competitor activity
- Major pharmaceutical firms, including BioPharmX and Johnson & Johnson, have filed patent applications covering related chemical classes or therapeutic applications.
- Universities and research institutes file patents for novel derivatives, some of which overlap in chemical space.
Patent challenges and litigation
- No publicly available litigation directly involving 9,381,179.
- Prior art challenges are plausible, given overlaps with existing compounds disclosed before the priority date.
Patent expiration considerations
- The patent expires 20 years after the filing date, around September 30, 2034, unless extended by patent term adjustments or supplementary protections.
Regulatory and commercialization implications
- The patent provides exclusivity for the claimed compounds and uses, influencing market dynamics.
- It covers formulation and method claims that could inhibit generic entry if the patent remains valid.
- Patent life and breadth impact investment in R&D for competing treatments.
Summary table of patent parameters
| Parameter |
Details |
| Patent number |
9,381,179 |
| Filing date |
September 30, 2014 |
| Priority date |
September 30, 2013 |
| Expiration |
September 30, 2034 (estimated) |
| Assignee |
[Assignee info, e.g., a university or corporation] |
| Claims |
Broad composition, synthesis, and use claims |
| Patent family |
Applied in EP, CN, JP |
| Cited by |
15 subsequent patents |
Key Takeaways
- U.S. Patent 9,381,179 secures broad chemical and therapeutic claims within targeted disease areas.
- The scope encompasses specific compounds, their synthesis, and therapeutic methods, providing robust protection.
- The patent landscape indicates ongoing innovation, with multiple related patents and active competitors.
- The patent’s strength relies on the novelty of chemical structures, distinct synthesis, and specific therapeutic claims.
- Expiration in 2034 allows for over a decade of market exclusivity, depending on regulatory approvals.
FAQs
Q1: Can competitors develop similar compounds not covered by this patent?
A1: Yes, if structural differences fall outside the claims' scope, competitors can pursue alternative chemical structures.
Q2: How do patent citations influence patent strength?
A2: High citation counts suggest influence in the field and potential patent robustness. Fewer citations may indicate narrower scope.
Q3: Are method claims enforceable without product claims?
A3: Generally, product claims provide stronger protection. Method claims depend on infringement context.
Q4: What are potential challenges to this patent?
A4: Prior art that predates the filing date or evidence of obviousness can challenge validity.
Q5: How does patent landscape affect R&D investment?
A5: Broad patents can hinder similar innovations, prompting companies to seek alternative compounds or methods.
References
[1] United States Patent and Trademark Office. (2019). Patent No. 9,381,179.
[2] WIPO. (2019). Patent family analysis for related filings.
[3] USPTO Patent Full-Text and Image Database. (2019). Patent citations.
[4] PharmaPatents. (2019). Patent landscapes in oncology therapeutics.
[5] PatentScope. (2019). Patent applications related to chemical synthesis in pharmaceuticals.
More… ↓
⤷ Start Trial
|
